Now showing items 1-3 of 3

    • Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia 

      Iacovelli, Stefano; Ricciardi, Maria Rosaria; Allegretti, Matteo; Mirabilii, Simone; Licchetta, Roberto; Bergamo, Paola; Rinaldo, Cinzia; Zeuner, Ann; Foá , Robin; Milella, Michele; McCubrey, James A.; Martelli, Alberto M.; Tafuri, Agostino (2015-10)
      Several chemo-resistance mechanisms including the Bcl-2 protein family overexpression and constitutive activation of the PI3K/Akt/mTOR signaling have been documented in acute lymphoblastic leukemia (ALL), encouraging ...
    • Emerging targeted therapies for melanoma treatment (Review) 

      Russo, Angela; Ficili, Bartolomea; Candido, Saverio; Pezzino, Franca Maria; Guarneri, Claudio; Biondi, Antonio; Travali, Salvatore; McCubrey, James A.; Spandidos Demetrios A.; Libra, Massimo (2014-08)
      Cutaneous melanoma is an aggressive cancer with a poor prognosis for patients with advanced disease. The identification of several key molecular pathways implicated in the pathogenesis of melanoma has led to the development ...
    • The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells 

      Simioni, Carolina; Cani, Alice; Martelli, Alberto M.; Zauli, Giorgio; Alameen, Ayman A.M.; Ultimo, Simona; Tabellini, Giovanna; McCubrey, James A.; Capitani, Silvano; Neri, Luca M. (2015-07)
      Hepatocellular carcinoma (HCC) is one of the most common lethal human malignancies worldwide and its advanced status is frequently resistant to conventional chemotherapeutic agents and radiation. We evaluated the cytotoxic ...